These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16876818)

  • 1. Cardiac energy metabolism alterations in angiotensin II induced hypertrophy.
    Lopaschuk GD
    J Mol Cell Cardiol; 2006 Sep; 41(3):418-20. PubMed ID: 16876818
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
    Jaffré F; Bonnin P; Callebert J; Debbabi H; Setola V; Doly S; Monassier L; Mettauer B; Blaxall BC; Launay JM; Maroteaux L
    Circ Res; 2009 Jan; 104(1):113-23. PubMed ID: 19023134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure.
    Lopaschuk GD
    Semin Cardiothorac Vasc Anesth; 2006 Sep; 10(3):228-30. PubMed ID: 16959756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of granulocyte colony-stimulating factor in angiotensin II-induced cardiac remodelling.
    Jia N; Dong P; Huang Q; Jin W; Zhang J; Dai Q; Liu S
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):262-6. PubMed ID: 18785976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heart energy metabolism and its role in the treatment of heart failure].
    Castro P; Gabrielli L; Verdejo H; Greig D; Mellado R; Concepción R; Sepúlveda L; Vukasovic JL; García L; Pizarro M; Pivet D; Carrillo C; Tapia F; Navarro M; Troncoso R; Baraona F; Llevaneras S; Hernández C; Godoy I; Jalil JE; Quintana JC; Orellana P; Chiong M; Lavandero S
    Rev Med Chil; 2010 Aug; 138(8):1028-39. PubMed ID: 21140063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Signalling in cardiac metabolism.
    Lopaschuk GD; Kelly DP
    Cardiovasc Res; 2008 Jul; 79(2):205-7. PubMed ID: 18515845
    [No Abstract]   [Full Text] [Related]  

  • 7. The heart requires glycerol as an energy substrate through aquaporin 7, a glycerol facilitator.
    Hibuse T; Maeda N; Nakatsuji H; Tochino Y; Fujita K; Kihara S; Funahashi T; Shimomura I
    Cardiovasc Res; 2009 Jul; 83(1):34-41. PubMed ID: 19297367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heart spotting.
    el Azzouzi H; De Windt LJ
    Basic Res Cardiol; 2008 May; 103(3):228-31. PubMed ID: 18274799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does angiotensin II-aldosterone have a role in radiation-induced heart disease?
    Wu R; Zeng Y
    Med Hypotheses; 2009 Mar; 72(3):263-6. PubMed ID: 19095366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin in the kidney: a key to understanding hypertension?
    Steckelings UM; Rettig R; Unger T
    Cell Metab; 2007 Jan; 5(1):7-8. PubMed ID: 17189202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines in heart failure: potential interactions with angiotensin II and leptin.
    Holycross BJ; Radin MJ
    Mol Interv; 2002 Nov; 2(7):424-7. PubMed ID: 14993404
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin AT2 receptor: the younger sibling attracts attention.
    Cerbai E; Mugelli A
    Cardiovasc Res; 2004 Apr; 62(1):7-8. PubMed ID: 15023548
    [No Abstract]   [Full Text] [Related]  

  • 13. K(ATP) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function.
    Gao S; Long CL; Wang RH; Wang H
    Cardiovasc Res; 2009 Aug; 83(3):444-56. PubMed ID: 19304734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy.
    Zhai P; Galeotti J; Liu J; Holle E; Yu X; Wagner T; Sadoshima J
    Circ Res; 2006 Sep; 99(5):528-36. PubMed ID: 16902180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
    Wang W; Lopaschuk GD
    Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1123-34. PubMed ID: 18035928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy?
    Balakumar P; Singh AP; Ganti SS; Krishan P; Ramasamy S; Singh M
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):5-9. PubMed ID: 17973902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The creatine kinase energy transport system in the failing mouse heart.
    Lygate CA; Fischer A; Sebag-Montefiore L; Wallis J; ten Hove M; Neubauer S
    J Mol Cell Cardiol; 2007 Jun; 42(6):1129-36. PubMed ID: 17481652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Western diet impairs metabolic remodelling and contractile efficiency in cardiac hypertrophy.
    Akki A; Seymour AM
    Cardiovasc Res; 2009 Feb; 81(3):610-7. PubMed ID: 19028723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of sodium houttuyfonate on myocardial hypertrophy in mice and rats.
    Gao JP; Chen CX; Wang Y; Lü J; Gu WL
    J Pharm Pharmacol; 2009 May; 61(5):677-83. PubMed ID: 19406008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
    McMullen JR; Jennings GL
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):255-62. PubMed ID: 17324134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.